Ondansetron

Late intrauterine deaths (> 22 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S2778
R4606		 Fejzo (Mainly exposed to other treatements, sick), 2016 Stillbirths (21-36 and 37-40 weeks) / Neonatal death 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 1.30 [0.43;3.89] C
excluded (control group) 		9/1,070   5/771 14 1,070
ref
S2776
R4607		 Fejzo (Unexposed control, disease free), 2016 Stillbirths (21-36 and 37-40 weeks) 1st trimester retrospective cohort unexposed, disease free Adjustment: No 1.19 [0.49;2.88] C 9/1,070   11/1,555 20 1,070
ref
S2775
R3715		 Colvin, 2013 Stillbirth during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.80 [0.60;5.50] -/263   635/98,062 - 263
ref
S2746
R3637		 Pasternak, 2013 Stillbirth (fetal loss after 22 weeks of gestation) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.42 [0.10;1.73] 6/1,915   27/7,660 33 1,915
ref
S2755
R3668		 Einarson (Control exposed to other antiemetics), 2004 Stillbirth (NOS) 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.33 [0.01;8.19] C
excluded (control group) 		0/176   1/176 1 176
ref
S2754
R3664		 Einarson (Unexposed control), 2004 Stillbirth (NOS) 1st trimester prospective cohort unexposed, disease free Adjustment: No 1.00 [0.02;50.68] C 0/176   0/176 0 176
ref
Total 4 studies 1.11 [0.60;2.05] 53 3,424
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Fejzo (Unexposed control, disease free), 2016Fejzo, 2016 1 1.19[0.49; 2.88]201,07048%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Colvin, 2013Colvin, 2013 1.80[0.60; 5.50]-26331%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Pasternak, 2013Pasternak, 2013 0.42[0.10; 1.73]331,91519%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Einarson (Unexposed control), 2004Einarson, 2004 2 1.00[0.02; 50.68]01762%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 0% 1.11[0.60; 2.05]533,4240.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Unexposed control, disease free; 2: Unexposed control;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.11[0.60; 2.05]533,4240%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Pasternak, 2013 Einarson (Unexposed control), 2004 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.11[0.60; 2.05]533,4240%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Pasternak, 2013 Einarson (Unexposed control), 2004 4 Tags Adjustment   - No  - No 1.38[0.70; 2.73]201,5090%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Einarson (Unexposed control), 2004 3   - Yes  - Yes 0.42[0.10; 1.75]331,915 -NAPasternak, 2013 1 All studiesAll studies 1.11[0.60; 2.05]533,4240%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Pasternak, 2013 Einarson (Unexposed control), 2004 40.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.74.82.4030.000Fejzo (Unexposed control, disease free), 2016Colvin, 2013Pasternak, 2013Einarson (Unexposed control), 2004

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 2755, 2778

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.11[0.60; 2.05]6793,4240%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Pasternak, 2013 Einarson (Unexposed control), 2004 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.13[0.40; 3.18]151,2460%NAFejzo (Mainly exposed to other treatements, sick), 2016 Einarson (Control exposed to other antiemetics), 2004 20.510.01.0